“Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson's disease expected later this year”10:46 PM"This acquisition marks a major milestone on our path towards a leading position in cell therapy," said Stefan Oelrich, Member of the Board of Management, Bayer AG and President Pharmaceuticals Division. "In line with our strategy to ramp up our investments in technologies with breakthrough innovation potential, we have decided to build our cell therapy pipeline based on BlueRock Therapeutics' industry-leading iPSC platform. Ultimately, we are joining forces to deliver new treatment options for medical needs that are still unmet today."
https://www.prnewswire.com/news-releases/bayer-acquires-bluerock-therapeutics-to-build-leading-position-in-cell-therapy-300898714.html
Fair Value Please, page-224
-
- There are more pages in this discussion • 246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $45.80M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.5¢ | $10.03K | 38.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27654 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.08pm 17/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |